

ASX Announcement

1 September 2025

## Director changes & office address update

Pharmx Technologies Limited (ASX:PHX) (**Pharmx** or the **Company**) advises of the following updates:

### Appointment of Mr. Alexander Mellis as Non-Executive Director

Pharmx is delighted to advise that Mr. Alexander (Sandy) Mellis has today been appointed as a full Non-Executive Director of the Company with immediate effect, having resigned from his position as an Alternate Director to Mr. Dennis Bastas.

Mr. Mellis has acted as an Alternate Director to Mr. Bastas since September 2024 and has provided invaluable contribution to the Board during this time. Mr. Mellis will continue to provide his 25+ years industry experience in consumer health brands and the Australian consumer goods market across a variety of market channels to the Company, having consented to a full position on the Board.

Mr. Mellis has been appointed to fill a casual vacancy in accordance with the Company's Constitution until the Company's 2025 Annual General Meeting (AGM) whereby Mr. Mellis will stand for election in accordance with the Company's Constitution and ASX Listing Rules.

The Company notes it was originally intended that Mr. Mellis remain as Alternate Director until the 2025 AGM where he was then due to step down as an Alternate Director and stand for election as a Non-Executive Director, however the Board (with Mr. Mellis' endorsement) has chosen to expedite the appoint of Mr. Mellis in light of the immediate resignation of Mr. Dennis Bastas (for which further information is provided below).

### Resignation of Mr. Dennis Bastas as Non-Executive Director

The Company has identified and acknowledges a breach of ASX Listing Rule 14.4 in relation to Mr. Bastas' current term as a Director of the Company.

At the 2024 AGM, Pharmx had planned to seek re-election of Mr. Bastas as a Non-Executive Director in accordance with the requirements under its Constitution and the ASX's Listing Rules, however due to an administrative oversight from its 2024 AGM the resolution was omitted from the Notice of Meeting, resulting in Mr. Bastas continuing as a Director for a period longer than the 3-year term stipulated by the ASX Listing Rules without standing for re-election.

Mr. Bastas, by mutual agreement with the Company, has resigned as a Director of the Company with immediate effect, allowing him to focus more fully on his position as Chairman & Group CEO of DBG Health. The Board wishes to acknowledge and thank Mr. Bastas for his contribution to the Board during his tenure.

### **Change of Registered Office Address**

The Company also wishes to advise that its Australian registered office address and principal business address changed to Suite 7.02, Level 7, 1 Castlereagh Street, Sydney 2000 with effect from 2 June 2025, and that late notification of this change is in contravention of ASX listing rule 3.14.

Pharmx acknowledges the breaches and is aware of its obligations under the Listing Rules and remains satisfied that the internal measures and processes currently in place are sufficient to ensure future compliance. Nonetheless, a full review of the current processes will be carried out as part of the review of company policies and charters regularly conducted.

**ENDS**

*This announcement has been authorised for lodgement by the Chairman.*

### **For further information contact:**

Tom Culver

Chief Executive Officer

[investor.relations@pharmx.com.au](mailto:investor.relations@pharmx.com.au)

### **About Pharmx Technologies Ltd.**

Pharmx is ANZ's leading pharmacy ordering platform, providing essential technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability platform – driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.